Navigation Links
Roche Real-Time HIV Test is Faster and Less Labor-Intensive Than Competitor's
Date:9/14/2007

Roche test processes 50 percent more samples in 1-day shift

INDIANAPOLIS, Sept. 14 /PRNewswire/ -- Roche Diagnostics' newly developed, automated real-time PCR test for HIV provides shorter turnaround time and less hands-on labor than one of its main competitors, according to a new study published in Clinical Chemistry and Laboratory Medicine in July.

The study, conducted by Medical Laboratory Bremen, concludes that Roche's new HIV-1 test used with the COBAS(R) Ampliprep/COBAS(R) TaqMan(R) (CAP/CTM) can save laboratories 30 minutes of workflow time and can process up to 50 percent more samples in a one-day shift, compared with Abbott's RealTime HIV test using m2000sp and m2000rt.

The research compared 102 plasma samples from HCV patients, 109 samples from HIV patients and 10 samples from negative donors. Roche has filed with the U.S. Food & Drug Administration for approval to use the HCV test on the CAP/CTM in the United States. The widely used, semi-automated COBAS Amplicor Monitor assay served as the reference test.

"The results indicate that real-time PCR assays can improve on the efficiency of end-point PCR tests by better covering viral dynamic ranges and providing high throughput and automation," said Dr. Dietmar Wolff, author of "Comparison of the Roche COBAS Amplicor Monitor, Roche COBAS Ampliprep/COBAS Taqman and Abbott RealTime Test assays for quantification of hepatitis C virus and HIV RNA."

In addition, the study highlighted some key performance differences between the COBAS Ampliprep/COBAS Taqman and Abbott RealTime assays using m2000sp and m2000rt.

Workflow is so critical to laboratories that Wolff wanted to develop a practical measurement by running the systems at full capacity in a one-day shift simulation.

"CAP/CTM could process 72 samples in a one-day shift, while RealTime could only process 48 samples," Wolff said. "This difference is due to the significant reduction in manual intervention required by CAP/CTM, an integrated system in which samples are processed for extraction and real-time PCR by two dedicated instruments physically linked by a robotic arm."

About Roche and the Roche Diagnostics Division

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of drugs for cancer and transplantation and a market leader in virology. In 2006, sales by the Pharmaceuticals Division totaled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Roche's Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our U.S. Web site at http://www.roche-diagnostics.us.

All trademarks used or mentioned in this release are legally protected by law.

For further information please contact:

Lori McLaughlin

Corporate Communications

Roche Diagnostics Corporation

Indianapolis, Ind.

Phone: 317-521-3112

lori.mclaughlin@roche.com


'/>"/>
SOURCE Roche Diagnostics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Advantages of Roche Applied Science amplification products
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. NimbleGen to discontinue IPO after Roches $272.5 million acquisition
5. Prodesse enters patent agreement with Roche
6. Critical factors for successful microarray and real-time PCR analyses
7. Measuring RNase Activity A Real-time Kinetic Analysis
8. Ready for Real-time in 5 Minutes
9. YOUR DATA: Direct Real-time RT-PCR on Sympathetic Neuron Lysates Silencing of Focal Adhesion Kinases with Silencer Validated siRNAs
10. YOUR DATA: Direct Real-time RT-PCR on Sympathetic Neuron Lysates Silencing of Focal Adhesion Kinases with Silencer Validated siRNAs
11. Detection of Genetically Modified Soybean in Processed Foods Using Real-Time Quantitative PCR with SYBR Green I Dye on the DNA Engine Opticon 2 System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, doctors ... being treated for breast cancer benefitted from an injection of stem cells derived from ... frequent side effect of cancer treatment. , Lymphedema refers to the swelling ...
Breaking Biology Technology:
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/22/2016)... PROVO and SANDY, ... Screening Ontario (NSO), which operates the highest sample volume ... testing, and Tute Genomics and UNIConnect, leaders in clinical ... today announced the launch of a project to establish ... testing panel. NSO has been contracted ...
Breaking Biology News(10 mins):